| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0166-3542(86)90024-0 |
| P698 | PubMed publication ID | 2429616 |
| P2093 | author name string | C J Peters | |
| D E Jones | |||
| J A Reynolds | |||
| E L Stephen | |||
| T W Slone | |||
| P433 | issue | 5 | |
| P921 | main subject | Rift Valley fever | Q326638 |
| Rift Valley fever phlebovirus | Q24809101 | ||
| P304 | page(s) | 285-297 | |
| P577 | publication date | 1986-08-01 | |
| P1433 | published in | Antiviral Research | Q4775352 |
| P1476 | title | Prophylaxis of Rift Valley fever with antiviral drugs, immune serum, an interferon inducer, and a macrophage activator | |
| P478 | volume | 6 |
| Q38614847 | A novel system for identification of inhibitors of rift valley Fever virus replication. |
| Q33621078 | A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge |
| Q28486013 | Aerosol exposure to Rift Valley fever virus causes earlier and more severe neuropathology in the murine model, which has important implications for therapeutic development |
| Q47547438 | Anti-Rift Valley fever virus activity in vitro, pre-clinical pharmacokinetics and oral bioavailability of benzavir-2, a broad-acting antiviral compound. |
| Q42254382 | Antiviral activity of GuiQi polysaccharides against enterovirus 71 in vitro |
| Q34992622 | Antiviral prophylaxis and treatment (excluding HIV therapy). |
| Q57008751 | Arboviruses and pregnancy: maternal, fetal, and neonatal effects |
| Q21092271 | Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational Rift Valley Fever |
| Q35000433 | Bunyamwera bunyavirus nonstructural protein NSs counteracts the induction of alpha/beta interferon. |
| Q56537260 | Bunyavirus: Hemorrhagic Fevers |
| Q41717722 | California-La Crosse encephalitis |
| Q33427270 | Combination effects of ribavirin and interferons on severe fever with thrombocytopenia syndrome virus infection |
| Q37282815 | Comparative study between Ribavirin and Ribavirin plus Intravenous Immunoglobulin against Crimean Congo hemorrhagic fever |
| Q33705717 | Countermeasure development for Rift Valley fever: deletion, modification or targeting of major virulence factor NSs |
| Q35126733 | Development of a novel, single-cycle replicable rift valley Fever vaccine |
| Q33433096 | Efficacy of T-705 (Favipiravir) in the Treatment of Infections with Lethal Severe Fever with Thrombocytopenia Syndrome Virus |
| Q40743768 | Efficacy of a Rift Valley fever virus vaccine against an aerosol infection in rats |
| Q34432483 | Efficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus disease models |
| Q40358602 | Evaluation of the efficacy and safety of the Rift Valley Fever Clone 13 vaccine in sheep |
| Q45751292 | Exotic virus infections of military significance. Hemorrhagic fever viruses and pox virus infections |
| Q36171757 | Extended protection against phlebovirus infection conferred by recombinant adenovirus expressing consensus interferon (DEF201) |
| Q37683496 | Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment |
| Q38778411 | Generation of a Single-Cycle Replicable Rift Valley Fever Vaccine |
| Q39601913 | Genetic evidence for an interferon-antagonistic function of rift valley fever virus nonstructural protein NSs |
| Q33439713 | Hemorrhagic fever of bunyavirus etiology: disease models and progress towards new therapies |
| Q24321691 | Human MxA protein inhibits the replication of Crimean-Congo hemorrhagic fever virus |
| Q40632227 | Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience. |
| Q27481401 | In Vitro and In Vivo Activities of T-705 against Arenavirus and Bunyavirus Infections |
| Q27480330 | Inhibition of bunyaviruses, phleboviruses, and hantaviruses by human MxA protein |
| Q40644135 | Inhibition of sandfly fever Sicilian virus (Phlebovirus) replication in vitro by antiviral compounds |
| Q45372924 | Interventions Against West Nile Virus, Rift Valley Fever Virus, and Crimean-Congo Hemorrhagic Fever Virus: Where Are We? |
| Q37103536 | Macaque models of human infectious disease |
| Q39195523 | NSs protein of rift valley fever virus induces the specific degradation of the double-stranded RNA-dependent protein kinase |
| Q36124734 | Oligonucleotides and polyribonucleotides: a review of antiviral activity |
| Q40768376 | Pathogenesis of Rift Valley fever in rhesus monkeys: role of interferon response |
| Q26747457 | Phleboviruses and the Type I Interferon Response |
| Q38699406 | Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow. |
| Q36879979 | Post-exposure vaccination with MP-12 lacking NSs protects mice against lethal Rift Valley fever virus challenge |
| Q28354111 | Predicting Rift Valley Fever Inter-epidemic Activities and Outbreak Patterns: Insights from a Stochastic Host-Vector Model |
| Q40883850 | Preferential infection of neuronal and astroglia cells by Akabane virus in primary cultures of fetal bovine brain |
| Q27485635 | Prophylactic and therapeutic intervention of Punta Toro virus (Phlebovirus, Bunyaviridae) infection in hamsters with interferon alfacon-1 |
| Q39467349 | Quantitative real-time PCR detection of Rift Valley fever virus and its application to evaluation of antiviral compounds |
| Q36759999 | RNA helicase signaling is critical for type i interferon production and protection against Rift Valley fever virus during mucosal challenge |
| Q27491320 | Rapid Accumulation of Virulent Rift Valley Fever Virus in Mice from an Attenuated Virus Carrying a Single Nucleotide Substitution in the M RNA |
| Q45324172 | Recent advances in the development of antiviral therapeutics for Rift Valley fever virus infection. |
| Q40744262 | Recombinant Human Interferon-γ Modulates Rift Valley Fever Virus Infection in the Rhesus Monkey |
| Q33570326 | Reverse genetics technology for Rift Valley fever virus: current and future applications for the development of therapeutics and vaccines |
| Q34750642 | Ribavirin reduces mortality in enterovirus 71-infected mice by decreasing viral replication |
| Q40777156 | Rift Valley fever infection of rhesus monkeys: implications for rapid diagnosis of human disease |
| Q26745530 | Rift Valley fever virus NSs protein functions and the similarity to other bunyavirus NSs proteins |
| Q28543047 | Rift Valley fever virus infection in golden Syrian hamsters |
| Q33960690 | Rift Valley fever virus(Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention |
| Q33760778 | Rift valley fever virus infection of human cells and insect hosts is promoted by protein kinase C epsilon |
| Q36326847 | Single-cycle replicable Rift Valley fever virus mutants as safe vaccine candidates |
| Q37673160 | Single-dose intranasal treatment with DEF201 (adenovirus vectored consensus interferon) prevents lethal disease due to Rift Valley fever virus challenge |
| Q40790822 | The gerbil, Meriones unguiculatus, a model for Rift Valley fever viral encephalitis |
| Q37156824 | Using a field quantitative real-time PCR test to rapidly identify highly viremic rift valley fever cases |
| Q40254473 | Virus-like particle-based countermeasures against Rift Valley fever virus |
| Q35077256 | Viruses of the Bunya- and Togaviridae families: potential as bioterrorism agents and means of control |
Search more.